



(51) International Patent Classification:

C07D 417/14 (2006.01) *A61P* 25/28 (2006.01)
A61K 31/4045 (2006.01)

(21) International Application Number:

PCT/US2015/013263

(22) International Filing Date:

28 January 2015 (28.01.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/933,246 29 January 2014 (29.01.2014) US
62/078,895 12 November 2014 (12.11.2014) US

(71) Applicant: **NEUROPORE THERAPIES, INC.** [US/US];
10835 Road to the Cure, Suite 210, San Diego, CA 92121
(US).

(72) Inventors: **STOCKING, Emily, M.**; c/o Neuropore Ther-
apies, Inc., 10835 Road to the Cure, Suite 210, San Diego,
CA 92121 (US). **WRASIDLO, Wolfgang**; c/o Neuropore
Therapies, Inc., 10835 Road to the Cure, Suite 210, San
Diego, CA 92121 (US).

(74) Agents: **MULLEN, James, J., III** et al.; Morrison & Foer-
ster LLP, 12531 High Bluff Drive, Suite 100, San Diego,
CA 92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HETEROARLY AMIDES AS INHIBITORS OF PROTEIN AGGREGATION

Figure 2



(57) Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.